Ironwood Pharmaceuticals: Today's Gains Seem Sustainable After Disastrous First Half Of 2025 [Seeking Alpha]
Ironwood Pharmaceuticals, Inc. - Class A (IRWD)
Last ironwood pharmaceuticals, inc. - class a earnings: 2/13 07:00 am
Check Earnings Report
US:NASDAQ Investor Relations:
investor.ironwoodpharma.com
Company Research
Source: Seeking Alpha
IRWD's apraglutide Phase 3 trial met primary endpoints but failed to surpass Takeda's Gattex, prompting the FDA to require another confirmatory study before approval. Linzess sales are robust, with Q3 2025 sales up 40% year-on-year and new pediatric approval, but looming 2029 patent expiry poses a long-term risk. Despite risks and recent setbacks, IRWD is a speculative Buy, as recovery momentum, strategic alternatives, and potential for apraglutide success offer upside from current lows. Hiroshi Watanabe/DigitalVision via Getty Images Ironwood Pharmaceuticals ( IRWD ) stock is buoyant today, up 15%, despite the CMS announcing the list price of its drug Linzess will be slashed from 2027, from $568 per month, to $136. The news is not as bad as feared, however, given drugs More on my IG service If you are interested in keeping up to date with stocks making moves within the biotech, pharma and healthcare industries, and understanding the key trends and catalysts driving val
Show less
Read more
Impact Snapshot
Event Time:
IRWD
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
IRWD alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
IRWD alerts
High impacting Ironwood Pharmaceuticals, Inc. - Class A news events
Weekly update
A roundup of the hottest topics
IRWD
News
- What Catalysts Are Shaping the Changing Narrative for Ironwood Pharmaceuticals? [Yahoo! Finance]Yahoo! Finance
- Ironwood Pharmaceuticals (NASDAQ:IRWD) had its price target raised by analysts at Wells Fargo & Company from $1.00 to $3.00. They now have an "equal weight" rating on the stock.MarketBeat
- Ironwood Pharmaceuticals Non-GAAP EPS of $0.24 beats by $0.12, revenue of $122.06M beats by $46.36M [Seeking Alpha]Seeking Alpha
- Ironwood Pharmaceuticals Reports Strong Third Quarter 2025 Results; Raises Full Year 2025 Financial GuidanceBusiness Wire
- Ironwood Pharmaceuticals (NASDAQ:IRWD) was downgraded by analysts at Zacks Research from a "strong-buy" rating to a "hold" rating.MarketBeat
IRWD
Earnings
- 11/10/25 - Beat
IRWD
Sec Filings
- 11/26/25 - Form 8-K
- 11/19/25 - Form 4
- 11/14/25 - Form 144
- IRWD's page on the SEC website